ES
MARKETS / NASDAQ / NXL
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Nexalin Technology, Inc. NXL

5 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$301,647
▲ 78.8% vs FY2024
EPS · FY25
$-0.50
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-221.5%
Net margin · FY25
-2725.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 301,647.00
Revenue, FY2025 · full 5-year series below
Revenue Net income
0.00040.00080.00120.00160.0-0.0202120242025
0.00040.00080.00120.00160.0-0.0202120242025

The company lost 2726 cents on every revenue dollar this year.

Per share
USD -0.50
Diluted EPS, FY2025
EPS
0.40.81.2-0.50202120242025
0.40.81.2-0.50202120242025

The company pays no cash dividend.

Profitability
-221.5%
Return on equity, FY2025
ROE
0.250.50.751-221.5%202120242025
0.250.50.751-221.5%202120242025
Operating margin-2781.7%
Net margin-2725.8%
Return on assets-185.6%

Each USD of equity lost 222 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−38.9%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.02B
Shares outstanding, FY2025
0.000.02202120242025
0.000.02202120242025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 4.6M
total assets, end of FY2025
Total assetsUSD 4.6M
EquityUSD 3.7M
CashUSD 654,783.00
Current ratio4.85×

Equity funds 81% of total assets.

History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
Revenue $B
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.50
−0.83
−0.63
−0.30
·
Dividend / sh $
·
·
·
·
·
Payout %
·
·
·
·
·
ROE %
−221.5
−221.1
−107.0
−89.4
·
Shares out B
0.02
0.01
0.01
0.01
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
19 of 19
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed